Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease

Launched by UNIVERSITY OF ROCHESTER · Dec 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a supplement called sulforaphane (SFN) to see if it is safe and well-tolerated in children with chronic kidney disease (CKD). The goal is to find out the right dose for kids and to look for any changes in certain markers in the body that indicate inflammation or oxidative stress, which are concerns for children with CKD. This study is currently active but not recruiting new participants.

To be eligible for the trial, children must be diagnosed with chronic kidney disease and have a specific level of kidney function (measured by eGFR between 20-59 mL/min/1.73m²). Parents must be able to give consent for their child’s participation. However, children who weigh less than 30 kg, have certain serious health conditions like cancer or HIV, or are currently taking specific medications will not be able to join. Participants can expect to receive SFN and will be monitored for how well they tolerate it and any side effects. It's important for parents to know that this is a research study aimed at finding new treatments for kidney disease in children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of chronic of kidney disease
• • have eGFR 20-59 mL/min/1.73m2 at the time of enrollment
• • parents must be able to provide consent
• Exclusion Criteria:
• • weight \<30 kg
• • cancer or HIV diagnosis
• • history of solid organ transplantation (including kidney transplant)
• • structural heart disease
• • currently pregnant or plan to become pregnant
• • life expectancy is less than one year
• • Patients will also be excluded if they are currently taking anticoagulants, immunosuppression, or chemotherapeutics